F ungal infections represent a very important complication observed in patients with hematologic malignancies. In a recent epidemiological multicenter survey conducted in Italy between 1999 and 2003 we observed that aspergillosis is the most frequent fungal complication among patients treated with conventional chemotherapies, followed by candidemia. 1 The same trend emerged in patients receiving allogeneic transplant, among whom aspergillosis reaches 81% of all fungal infections. 2 For this reason it must be considered the fungal complication in hematologic patients. Some institutions reported a predominance of emerging aspergillus species, such as A. terreus or A. flavus 3 but this trend was not confirmed in our experience. 1 
Clinical manifestations
The lung continues to represent the most frequently involved site. Pulmonary infection can be understood as a phenotypical representation of interaction between lowered defence mechanisms in the host and the virulence of invading fungus. Sinuses or lower respiratory tract are common portals of entry. From here aspergillus can first reach lung tissue and eventually spread to all other organs. Its pathogenetic mechanisms are well-known: after a colonization of the lower respiratory tract by conidia, the spores germinate and invade surrounding tissues, producing acute, necrotizing pneumonia. Frequently vascular walls are then infiltrated and the formation of fungal embolus is possible. Possible late consequences are pulmonary infarction followed by cavitation and bleeding which can be fatal.
Cough and fever are the most typical symptoms, even if patients can remain completely asymptomatic, despite the aspergillosis. 4 It is worth noting that some clinical manifestations, (i.e. hemoptysis or pneumothorax) can onset after recovering from infection. These complications are responsible for an increased risk of death even in patients with hematologic complete remission. [5] [6] These two dramatic events refer to the quick increase of normal white blood cells, which induces the release of cytokines and the subsequent destruction of the vessels near the aspergillus ball. In these cases, angiography with vessel embolization has both a diagnostic and therapeutic role. 
Diagnostic procedures
The most important factor in the management of aspergillosis is a timely and correct diagnosis. It is mandatory to identify the fungal agent because of the different sensibility spectrum to available drugs. For example, voriconazole, the first-choice drug for aspergillosis, does not cover zygomycetes.
Available instruments for a correct diagnosis are microbiology, radiology and histopathology. Microbiology includes direct microscopy and culture, which are good tools but in some cases disadvantages exceed the advantages (Table 1) . Some authors suggest that it could be better to perform such microbiological tests on bronchoalveolar lavage rather than on sputum. However, data from literature do not support this view. 8 Over recent years, other diagnostic platforms that are not based on culture have been investigated. The galactomannan antigenemia enzyme immunoassay (GM-EIA) has entered current use with discrepant results. [9] [10] [11] [12] [13] [14] This variability is probably due to possible bias that could influence this test (i.e. diet, antibiotic and antifungal treatment, infection by other fungi containing a cross-reactive GM, etc.). A recent metaanalysis reported a sensitivity of 79% and a specificity of 86%, with an overall accuracy of 89%. 15 The test should be performed twice weekly and positivity is defined by at least two consecutive tests with GM index ≥0.5. Given that a negative result does not exclude the diagnosis and viceversa, the most correct way to use such a test is to consider GM-EIA results in the context of clinical, radiological, and laboratory findings. GM-EIA can also help improve sensitivity of microbiological tests on BAL. In a study published by Becker et al., 16 in patients with IA a positivity of 100% was reported, compared to 47% achieved in serum samples. An interesting use of GM concerns a serial assessment of the test to monitor therapy. 17, 18 Survival correlates with antigenemia declining during antifungal treatment; this observation can help clinicians to differentiate between patients with persistent antigenemia requiring treatment modification, and patients with progressively lower GM index who do not necessarily require any change, even when radiological images have worsened after neutrophil recovery. 19 However, prospective studies on this topic are needed. Identification of fungal species by PCR offers a wide range of identification; the use of PCR in BAL samples has been investigated with reasonable sensitivity and specificity in patients at high risk for IA (79% and 94% respectively), 20 even with higher costs compared to GM-EIA. However, many other questions should be answered before confirming the utility of PCR in the diagnosis of IA (optimal specimen type, DNA extraction method, primer specificity, PCR format): the lack of this information means these results are still difficult to interpret. 13, 14, 21, 22 As for radiological tools, standard X-ray is the first line approach, even if it is not diagnostic in the majority of cases: hematologic patients typically have a decreased inflammatory response and clinical features, although variable and usually non-specific, may not manifest before the infection is far advanced. Thorax CT-scan, and particularly high resolution CTscan (HRCT-scan), offer a better approach: different studies showed a sensitivity and specificity of nearly 23 HRCT-scan can give us more information about type, number, localization of lesions, and their morphological characteristics. It can demonstrate the presence of the halo sign, a typical precocious lesion, or the presence of the air crescent sign, which usually becomes more prevalent later in the course of the disease. Calliot and colleagues provide a cornerstone study. They monitored pulmonary aspergillosis with seriated lung CT-scan and described the different radiological manifestations on the basis of the time elapsed. 19 Of particular interest is a recent study showing that the presence of a halo sign at baseline is associated with a significantly higher global response rate and better survival. 24 This observation could have been a result of the earlier initiation of antifungal therapy in the course of the fungal disease, since the halo sign is the earliest radiological manifestation of invasive pulmonary aspergillosis in neutropenic patients. Despite their importance, characteristic radiological patterns do not allow us to diagnose a certain aspergillosis, because of the similarity with other angioinvasive fungi, such as zygomycetes, fusarium spp or scedosporium spp. Surprisingly, even non-fungal agents, such as pseudomonas aeruginosa and nocardia, can mimic aspergillosis CT-scan appearance. This makes biopsy necessary to clarify the diagnosis. A prospective study conducted by Lass-Florl and colleagues in [2003] [2004] [2005] [2006] , evaluated the utility of CT-guided lung biopsy for diagnosis of IFI, by combining Calcolfuor white staining, GM-EIA and PCR on biopsy specimens. This combination resulted in a fast and reliable identification of the fungus, with a specificity and sensitivity of 100%. However the utility of such a diagnostic platform is doubtful, because of the many contraindications when performing invasive procedure in hematologic patients (i.e. thrombocytopenia, hemodynamic instability). 25, 26 More recently, the usefulness of PET-scan has been evaluated, but present data are very scarse. 27 An ideal diagnostic work-up may combine both microbiological and radiological exams. Maertens et al. suggested an approach with a daily GM monitoring closely linked to clinical evaluation, serial sinopulmonary CT-scan and bronchoalveolar-lavage. 28 This combined work-up allowed a reduction in incorrect diagnosis of pulmonary aspergillosis. However, a similar approach is not always practicable in current practice because it is too expensive and time-consuming, and also because of a lack of general accessibility in many centers.
Pulmonary aspergillosis in hematologic malignancies: lights and shadows

Treatments and guidelines
It is noteworthy that the aspergillosis mortality rate varies according to the different sites of infection. Almost all patients present with disseminated aspergillosis. An improved outcome using voriconazole treatment for central nervous system aspergillosis has been reported by Schwartz et al. 29 Mortality rate is instead lower for pulmonary localization. 30 During the last years we observed a stationary/increasing incidence of aspergillosis both in acute leukemia and in allogeneic transplant recipients; conversely, the mortality rate significantly decreased.
1,2 This is probably due to multiple cofactors, such as advances in diagnostic approach and new treatment options.
Different antifungal treatment approaches can be applied: prophylaxis, empirical therapy, pre-emptive therapy and target-therapy.
Recent studies evaluated the efficacy of caspofungin, voriconazole, liposomal amphotericin B, micafungin and posaconazole as prophylaxis. [31] [32] [33] [34] [35] [36] [37] However, it is still to be decided which is the best choice of treatment. Posaconazole seems to be better when compared to others, since not only is it active in vitro against a wide range of yeasts (including candida species) and molds (including aspergillus species, zygomycetes, and fusarium species) but also appears to have an acceptable adverse-event profile and it is well tolerated. However, the high number of patients eligible for prophylaxis and the long mean duration of such a treatment makes it a very expensive strategy, limiting its use. It would be necessary to define the population for whom prophylaxis would be most beneficial also on the basis of local epidemiology. 38 An empirical approach implies the commencement of antifungal therapy at the first clinical suspicion of a possible fungal infection (generally a persistent fever despite broad-spectrum antibiotics). Some authors believe this approach results in significant overtreatment and expenditure, and in an increasing incidence of breakthrough fungal infections. Maertens et al. 22 indicated the pre-emptive approach supported by a more intensive use of surrogate markers of aspergillosis (i.e. abnormalities in CT-scan findings, antigen assay) as an ideal strategy in an attempt to reduce exposure to antifungal agents. However, a recent randomized study by Cordonnier et al. showed that the empirical approach could have the same efficacy at the same cost. 39 Reviewing data from literature, first and second line antifungal approaches were suggested in treating pulmonary aspergillosis. The US Food and Drugs Administration (FDA) and the European Medicines Agency (EMEA) approved only for aspergillosis voriconazole and L-AMB for first line treatment, leaving caspofungin and posaconazole for the salvage therapy. Over the last few years, however, several studies have been conducted where these latter and other antifungal drugs have been used in first line therapy. [40] [41] [42] [43] [44] [45] [46] [47] Efficacy data of some of these studies are summarized in Table  2 . In our opinion, reported percentages of responders could be different from those really observed in clinical practice because of a selection bias in the enrollement of patients in experimental trials and the very restrictive criteria for the evaluation of response.
Following published randomized studies, guidelines by several co-operative groups and international societies (i.e IDSA, ECIL etc) have been revised, to summarize the current evidence for treatment of aspergillosis (Table 3) . 48, 49 Table 3 reports a comparison of the strength of recommendation and quality of evidence of the different groups for the use of antifungal agents in primary and salvage therapy of invasive pulmonary aspergillosis. All the guidelines are concordant in recommending voriconazole as the drug of choice for the primary treatment of invasive pulmonary aspergillosis (AI). L-AMB is also considered an alternative primary therapy in some patients in all guidelines, even though with a different grade of recommendation. L-AMB, ABLC, caspofungin, posaconazole and itraconazole are indicated in salvage therapy for patients refractory to or intolerant of primary antifungal therapy. Combination therapy of invasive fungal infections is attractive from the perspective of synergistic potential, but in the absence of a well-controlled, prospective clinical trial, its use for primary therapy is not routinely recommended. It is, however, recognized to have a possible role, with different recommendation grades, in salvage therapy.
Surgery should also be considered as a possible treatment option for pulmonary aspergillosis. In the different guidelines, surgical resection of aspergillusinfected tissue is indicated as useful in patients with lesions that are contiguous with the great vessels or causing hemoptysis. It is then suggested in patients with a documented aspergillosis (i.e. a single nodule) who have a transplant program, due to their propensity to reactivate in the setting of continued immuno- suppression. 50 The new IDSA takes granulocyte transfusions into consideration for the treatment of patients with invasive pulmonary aspergillosis. 51, 52 The rationale for improved outcome appears to be an adequate number of granulocytes transfused to the profoundly neutropenic patient. The real benefit of this procedure is not clarified and a precise grade of recommendation is lacking in IDSA guidelines. This option is, however, considered to be useful in the course of very severe refractory infections. In our opinion, one of the problems of this procedure in patients with acute leukemia is the possible immunization if relatives are used as donors since this could preclude a future allogeneic stem cell transplantation.
Final consideration
In conclusion, the population of patients at risk for pulmonary aspergillosis is expanding; it continues to represent the most relevant fungal complication. The emergence of other molds and yeasts observed in some centers has not been confirmed worldwide. The introduction of new antifungal molecules has modified patients' life-expectancy. However, outcome should be further improved by establishing a more timely diagnosis and anticipating targeted therapy. Many questions remain unanswered about the optimal treatment of such a complication, in particular about the management of refractory patients and the utility of combined therapies. 
